Katrin Gisselfält is stepping down as Head of Research and
Development at Artimplant to take up a position at another
company.
Lars Peterson will take over as Head of Research and
Development until a suitable permanent solution has been
found. Lars Peterson has been a member of the Artimplant
Board of Directors since 2011. He is also emeritusprofessor
at the Sahlgrenska Academy, Gothenburg University, and he
conducts research into tissue regeneration.
CEO Kjell Thörnbring states that with Lars Peterson as
Head of Research and Development, the company will be
reinforced considerably. “His background as an
internationally recognized and highly valued orthopedic
surgeon will add a dimension that has not existed at
Artimplant for many years. As an innovator and co-founder
of the company, Lars Peterson represents a link back to the
original concept of satisfying medical needs. I'm
extremely pleased that he is willing and able to take on
the task of developing and reinforcing the company's
products and services."
            Â
For additional information, please contact:
Kjell Thörnbring, CEO, phone +46 (0)703 11 90 25,
kjell.thornbring@artimplant.com
Further information is available at www.artimplant.com. To
subscribe to future press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant
Artimplant is a biomaterials company focused on solutions
to problems in orthopedic and oral surgery. We restore
health through the development, production and marketing of
degradable implants that regenerate body functions and
improve quality of life. Our products, made from Artelon®,
meet unmet clinical needs and are marketed in a growing
number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet, for shoulder
and other soft tissue injuries as well as oral surgery and
veterinary medical applications.
Artimplant is a public company listed on the NASDAQ OMX
Stockholm Exchange in the Small Cap segment and in the
healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as
defined in the U.S. Private Securities Litigation Reform
Act of 1995. Readers are cautioned not to place undue
reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and
uncertainties impacting the Company's business
including increased competition; the ability of the Company
to expand its operations and to attract and retain
qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from
time to time in the Company's filings.
This is information which Artimplant shall make public
pursuant to the Swedish Financial Instruments Act and the
Swedish Securities Exchange and Clearing Operations Act
and/or stock market agreements. Information was made
available for publication on August 21, 2012 at 4:30 PM
(Swedish time).
The following files are available for download:
distributed by
|